Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan
- Development stage
- Phase 2
- Lead developer
- Ipsen
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Liposomal irinotecan is a nanoparticle-encapsulated formulation of the topoisomerase I inhibitor irinotecan, designed to enhance the delivery and metabolic conversion of the drug into its active form, SN-38, within tumor tissues. By utilizing a liposomal delivery system, the drug achieves a longer half-life and higher concentration of SN-38 in the tumor microenvironment compared to conventional irinotecan, while potentially mitigating systemic side effects. In the context of clinical research at Hebei Medical University Fourth Hospital, liposomal irinotecan is being evaluated as part of a neoadjuvant chemoradiation regimen for locally advanced rectal cancer. This specific application often involves UGT1A1 genotype-guided dosing to personalize treatment and manage potential toxicities such as neutropenia and diarrhea.
- Brand names
- OnivydeDuoenda
- Other names
- irinotecan liposomeirinotecan sucrosofate liposome injectionnanoliposomal irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on liposomal irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan.